Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037475 | 0.83 | MAOB (0.56) | HIF1AMAOBMAPTALOX12MEN1 | |
| SCHEMBL11983159 | 0.83 | APLNR (0.65) | HIF1AMAOBMAPTALOX12MEN1 | |
| SCHEMBL10925241 | 0.81 | SMN1; SMN2 (0.54) | HIF1AMAOBMAPTMEN1KMT2A | |
| SCHEMBL14100516 | 0.79 | HIF1A (0.58) | HIF1AMAOBMAPTALOX12MEN1 | |
| SCHEMBL31478745 | 0.78 | MAPT (0.60) | MAOBMAPTALOX12MEN1KMT2A | |
| SCHEMBL13887881 | 0.78 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL10886823 | 0.78 | CA1 (0.72) | HIF1AMAOBMAPTALOX12CA1 | |
| SCHEMBL31011719 | 0.77 | HIF1A (0.52) | HIF1AMAOBMAPTALOX12MEN1 | |
| SCHEMBL20236579 | 0.77 | HIF1A (0.62) | HIF1AMAPTMEN1KMT2ACA1 | |
| SCHEMBL27569429 | 0.76 | HTR2A (0.48) | MAOBMAPTMEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027156-A1 | Crf antagonists and heterobicyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1666468-A1 | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027156-A1 | Crf antagonists and heterobicyclic compounds | CRHR2, CRHR1, CRH | HIF1A 1006/4885MAOB 348/4885MAPT 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.